Specific Drugs
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs

https://doi.org/10.1016/j.jaip.2020.08.006Get rights and content

Abbreviations used

ACD
Allergic contact dermatitis
ADR
Adverse drug reaction
AERD
Aspirin-exacerbated respiratory disease
AGEP
Acute generalized exanthematous pustulosis
ART
Antiretroviral
BAT
Basophil activation test
COPD
Chronic obstructive pulmonary disease
COX
Cyclooxygenase
CYC
Cyclophosphamide
CYP450
Cytochrome p450
DHR
Delayed hypersensitivity reaction
DMCD
Direct mast cell degranulation
DRESS
Drug rash (or reaction) with eosinophilia and systemic symptoms
EAACI
European Academy of Allergy and Clinical Immunology
EGFR
Epidermal growth factor receptor
EMB
Ethambutol
ENDA
European Network of Drug Allergy
FDA
Food and Drug Administration
HCV
Hepatitis C virus
HIT
Heparin-induced thrombocytopenia
HMW
High molecular weight
IDT
Intradermal test
IM-ADR
Immunologically mediated adverse drug reaction
INH
Isoniazid
LA
Local anesthetic
LMWH
Low-molecular-weight heparin
MM
Multiple myeloma
MTX
Methotrexate
NMBA
Neuromuscular-blocking agent
NSAID
Nonsteroidal anti-inflammatory drug
PH
Progestogen hypersensitivity
PI
Protease inhibitor
PPI
Proton pump inhibitor
PPL
Penicilloyl-polylysine
PT
Prick test
PZA
Pyrazinamide
RCM
Radiocontrast media
RMS
Red men syndrome
SCAR
Severe cutaneous adverse reaction
SJS
Stevens-Johnson syndrome
SMZ-TMP
Sulfamethoxazole-trimethoprim
SPT
Skin prick test
TB
Tuberculosis
TEN
Toxic epidermal necrolysis
TKI
Tyrosine kinase inhibitor
UFH
Unfractionated heparin
vWD
von Willebrand disease

Cited by (0)

Conflicts of interest: K. Blumenthal reports grants from the National Institutes of Health (NIH), CRICO, American Academy of Allergy, Asthma, and Immunology (AAAAI) Foundation, and Massachusetts General Hospital; and a beta-lactam allergy clinical decision support tool licensed to Persistent Systems. K. Buchheit receives royalties from UpToDate and grant support from NIAID. K. N. Cahill receives grant support from NIAID. A. M. Chiriac was part of the HYCOR Scientific Advisory Board for biology of drug hypersensitivity. P. Dewachter is on the advisory board dedicated to “Neuromuscular blocking agents and fast-tracking anesthesia” for MSD France and receives lecture and travel fees from MSD France, outside of the submitted work. M. P. Giannetti receives research funding and salary support from Blueprint Pharmaceuticals, not relevant to this article. J. T. Hsu reports consulting fees from EBSCO, grants from Vedanta Biosciences, outside the submitted work. T. Kyin is on an advisory board for Sanofi Regeneron. M. Louisias reports grants from Brigham and Women's Hospital, Agency for Healthcare Research and Quality (AHRQ), and NIH. S. Patil receives royalties from UpToDate for writing on a different topic and research funding from the NIH National Institute of Allergy and Infectious Diseases (NIAID) and the Charles H. Hood Foundation Child Health Grant on a different topic. E. J. Philips reports grants from NIH (P50GM115305, R01HG010863, R01AI152183, R21AI139021, U01AI154659) and from the National Health and Medical Research Council of Australia; receives royalties from UpToDate and consulting fees from Biocryst; is co-director of IIID Pty Ltd that holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity; and holds a patent for Detection of Human Leukocyte Antigen-A*32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. A. Romano is a consultant for Diater SA (Leganés, Spain). C. A. Stone Jr receives funding support from AHRQ (K12HS026395) for research in risk-stratified management of penicillin allergy. P. Wickner receives support from a CRICO grant that is not relevant to the content of this article. The rest of the authors declare that they have no relevant conflicts of interest.

This article is published as part of a supplement supported by the American Academy of Allergy, Asthma & Immunology.

View Abstract